1
|
Anti-Osteoporosis Effects of the Fruit of Sea Buckthorn ( Hippophae rhamnoides) through Promotion of Osteogenic Differentiation in Ovariectomized Mice. Nutrients 2022; 14:nu14173604. [PMID: 36079860 PMCID: PMC9460184 DOI: 10.3390/nu14173604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2022] [Revised: 08/24/2022] [Accepted: 08/29/2022] [Indexed: 11/16/2022] Open
Abstract
The fruit of Hippophae rhamnoides has been widely used for medicinal purposes because of its anti-inflammatory, antioxidant, antiplatelet, and antimicrobial effects. Since there are no clear reports on the therapeutic efficacy of H. rhamnoides in osteoporosis, this study aimed to confirm the potential use of H. rhamnoides for the treatment of osteoporosis through its osteogenic differentiation-promoting effect in ovariectomized mice. Through an in vitro study, we compared the effects of the EtOH extract of H. rhamnoides fruits (EHRF) on the differentiation of C3H10T1/2, a mouse mesenchymal stem cell line, into osteoblasts based on alkaline phosphatase (ALP) staining and the relative expression of osteogenesis-related mRNAs. The EHRF significantly stimulated the differentiation of mesenchymal stem cells into osteoblasts and showed 7.5 times (* p < 0.05) higher osteogenesis than in the untreated control. A solvent fractionation process of EHRF showed that the hexane-soluble fraction (HRH) showed 10.4 times (** p < 0.01) higher osteogenesis than in the untreated control. Among the subfractions derived from the active HRH by preparative HPLC fractionation, HRHF4 showed 7.5 times (* p < 0.05) higher osteogenesis than in the untreated naïve cells, and HRH and HRHF4 fractions showed 22.6 times (*** p < 0.001) stronger osteogenesis activity than in the negative control. Osteoporosis was induced by excision of both ovaries in 9-week-old female ICR mice for in vivo analysis, and two active fractions, HRH and HRHF4, were administered orally for three months. During the oral administration period, body weight was measured weekly, and bone mineral density (BMD) and body fat density were measured simultaneously using a DEXA machine once a month. In particular, during the in vivo study, the average BMD of the ovariectomized group decreased by 0.0009 g/cm2, whereas the average BMD of the HRH intake group increased by 0.0033 g/cm2 (* p < 0.05) and that of the HRHF4 intake group increased by 0.0059 g/cm2 (** p < 0.01). The HRH and HRHF4 intake groups significantly recovered the mRNA and protein expression of osteogenic genes, including ALP, Osteopontin, Runx2, and Osterix, in the osteoporosis mouse tibia. These findings suggest that the active fractions of H. rhamnoides fruit significantly promoted osteoblast differentiation in mesenchymal stem cells and increased osteogenic gene expression, resulting in an improvement in bone mineral density in the osteoporosis mouse model. Taken together, H. rhamnoides fruits are promising candidates for the prevention and treatment of osteoporosis.
Collapse
|
2
|
Uehara S, Mukai H, Yamashita T, Koide M, Murakami K, Udagawa N, Kobayashi Y. Inhibitor of protein kinase N3 suppresses excessive bone resorption in ovariectomized mice. J Bone Miner Metab 2022; 40:251-261. [PMID: 35028715 DOI: 10.1007/s00774-021-01296-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Accepted: 11/15/2021] [Indexed: 11/25/2022]
Abstract
INTRODUCTION The long-term inhibition of bone resorption suppresses new bone formation because these processes are coupled during physiological bone remodeling. The development of anti-bone-resorbing agents that do not suppress bone formation is urgently needed. We previously demonstrated that Wnt5a-Ror2 signaling in mature osteoclasts promoted bone-resorbing activity through protein kinase N3 (Pkn3). The p38 MAPK inhibitor SB202190 reportedly inhibited Pkn3 with a low Ki value (0.004 μM). We herein examined the effects of SB202190 on osteoclast differentiation and function in vitro and in vivo. MATERIALS AND METHODS Bone marrow cells were cultured in the presence of M-csf and GST-Rankl to differentiate into multinucleated osteoclasts. Osteoclasts were treated with increasing concentrations of SB202190. For in vivo study, 10-week-old female mice were subjected to ovariectomy (OVX). OVX mice were intraperitoneally administered with a Pkn3 inhibitor at 2 mg/kg or vehicle for 4 weeks, and bone mass was analyzed by micro-CT. RESULTS SB202190 suppressed the auto-phosphorylation of Pkn3 in osteoclast cultures. SB202190 significantly inhibited the formation of resorption pits in osteoclast cultures by suppressing actin ring formation. SB202190 reduced c-Src activity in osteoclast cultures without affecting the interaction between Pkn3 and c-Src. A treatment with SB202190 attenuated OVX-induced bone loss without affecting the number of osteoclasts or bone formation by osteoblasts. CONCLUSIONS Our results showed that Pkn3 has potential as a therapeutic target for bone loss due to increased bone resorption. SB202190 is promising as a lead compound for the development of novel anti-bone-resorbing agents.
Collapse
Affiliation(s)
- Shunsuke Uehara
- Department of Biochemistry, Matsumoto Dental University, Nagano, 399-0781, Japan
| | - Hideyuki Mukai
- Biosignal Research Center, Kobe University, Hyogo, 657-8501, Japan
- Department of Clinical Laboratory, Kitano Hospital, Osaka, 530-8480, Japan
| | - Teruhito Yamashita
- Institute for Oral Science, Matsumoto Dental University, 1780 Gobara, Hiro-oka , Shiojiri-shi, Nagano, 399-0781, Japan
| | - Masanori Koide
- Institute for Oral Science, Matsumoto Dental University, 1780 Gobara, Hiro-oka , Shiojiri-shi, Nagano, 399-0781, Japan
| | - Kohei Murakami
- Laboratory of Immunology, Faculty of Veterinary Medicine, Okayama University of Science, Ehime, 794-8555, Japan
| | - Nobuyuki Udagawa
- Department of Biochemistry, Matsumoto Dental University, Nagano, 399-0781, Japan
| | - Yasuhiro Kobayashi
- Institute for Oral Science, Matsumoto Dental University, 1780 Gobara, Hiro-oka , Shiojiri-shi, Nagano, 399-0781, Japan.
| |
Collapse
|
3
|
Baral K, Adhikari P, Jawad B, Podgornik R, Ching WY. Solvent Effect on the Structure and Properties of RGD Peptide (1FUV) at Body Temperature (310 K) Using Ab Initio Molecular Dynamics. Polymers (Basel) 2021; 13:3434. [PMID: 34641249 PMCID: PMC8512769 DOI: 10.3390/polym13193434] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Revised: 09/27/2021] [Accepted: 09/29/2021] [Indexed: 12/13/2022] Open
Abstract
The structure and properties of the arginine-glycine-aspartate (RGD) sequence of the 1FUV peptide at 0 K and body temperature (310 K) are systematically investigated in a dry and aqueous environment using more accurate ab initio molecular dynamics and density functional theory calculations. The fundamental properties, such as electronic structure, interatomic bonding, partial charge distribution, and dielectric response function at 0 and 310 K are analyzed, comparing them in dry and solvated models. These accurate microscopic parameters determined from highly reliable quantum mechanical calculations are useful to define the range and strength of complex molecular interactions occurring between the RGD peptide and the integrin receptor. The in-depth bonding picture analyzed using a novel quantum mechanical metric, the total bond order (TBO), quantifies the role played by hydrogen bonds in the internal cohesion of the simulated structures. The TBO at 310 K decreases in the dry model but increases in the solvated model. These differences are small but extremely important in the context of conditions prevalent in the human body and relevant for health issues. Our results provide a new level of understanding of the structure and properties of the 1FUV peptide and help in advancing the study of RGD containing other peptides.
Collapse
Affiliation(s)
- Khagendra Baral
- Department of Physics and Astronomy, University of Missouri-Kansas City, Kansas City, MO 64110, USA; (K.B.); (P.A.); (B.J.)
| | - Puja Adhikari
- Department of Physics and Astronomy, University of Missouri-Kansas City, Kansas City, MO 64110, USA; (K.B.); (P.A.); (B.J.)
| | - Bahaa Jawad
- Department of Physics and Astronomy, University of Missouri-Kansas City, Kansas City, MO 64110, USA; (K.B.); (P.A.); (B.J.)
| | - Rudolf Podgornik
- School of Physical Sciences, Kavli Institute of Theoretical Science, University of Chinese Academy of Sciences, Beijing 100049, China;
- CAS Key Laboratory of Soft Matter Physics, Institute of Physics, Chinese Academy of Sciences, Beijing 100090, China
- Wenzhou Institute of the University of Chinese Academy of Sciences, Wenzhou 325000, China
- Department of Physics, Faculty of Mathematics and Physics, University of Ljubljana, SI-1000 Ljubljana, Slovenia
| | - Wai-Yim Ching
- Department of Physics and Astronomy, University of Missouri-Kansas City, Kansas City, MO 64110, USA; (K.B.); (P.A.); (B.J.)
| |
Collapse
|
4
|
Cho CS, Jeong HS, Kim IY, Jung GW, Ku BH, Park DC, Moon SB, Cho HR, Bashir KMI, Ku SK, Choi JS. Anti-osteoporotic effects of mixed compositions of extracellular polymers isolated from Aureobasidium pullulans and Textoria morbifera in ovariectomized mice. BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE 2018; 18:295. [PMID: 30400922 PMCID: PMC6220464 DOI: 10.1186/s12906-018-2362-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Accepted: 10/25/2018] [Indexed: 12/26/2022]
Abstract
Background Extracellular polymeric substances isolated from Aureobasidium pullulans (EAP), containing specifically 13% β-1,3/1,6-glucan, have shown various favorable bone-preserving effects. Textoria morbifera Nakai (TM) tree has been used as an ingredient in traditional medicine and tea for various pharmacological purposes. Thus, the present study was aimed to examine the synergistic anti-osteoporotic potential of mixtures containing different proportions of EAP and TM compared with that of the single formulations of each herbal extract using bilateral ovariectomized (OVX) mice, a renowned rodent model for studying human osteoporosis. Methods Thirty five days after bilateral-OVX surgery, 9 combinations of EAP:TM (ratios = 1:1, 1:3, 1:5, 1:7, 1:9, 3:1, 5:1, 7:1, 9:1) and single separate formulations of EAP or TM were supplied orally, once a day for 35 days at a final concentration of 200 mg/kg. Variations in body weight gains during the experimental periods, as well as femur weights, bone mineral density (BMD), bone strength (failure load), and mineral content (calcium [Ca] and inorganic phosphorus [IP]) following sacrifice were measured. Furthermore, histomorphometric and histological profile analyses of serum biochemical parameters (osteocalcin content and bone specific alkaline phosphatase [bALP] activity) were conducted following sacrifice. Femurs histomorphometric analyses were also conducted for bone resorption, structure and mass. The results for the mixed formulations of EAP:TM and separate formulations were compared with those of risedronate sodium (RES). Results The EAP:TM (3:1) formulation synergistically enhanced the anti-osteoporotic potential of individual EAP or TM formulations, possibly due to enhanced variety of the active ingredients. Furthermore, the effects of EAP:TM were comparable to those of RES (2.5 mg/kg) treatment. Conclusion The results of this study suggest that, the EAP:TM (3:1) combination might act as a new pharmaceutical agent and/or health functional food substance for curing osteoporosis in menopausal women. Electronic supplementary material The online version of this article (10.1186/s12906-018-2362-y) contains supplementary material, which is available to authorized users.
Collapse
|
5
|
Cho CS, Jeong HS, Kim IY, Jung GW, Ku BH, Park DC, Moon SB, Cho HR, Ku SK, Choi JS. Antiosteoporotic effects of 3:1 (g/g) mixed formulation of exopolymers purified fromAureobasidium pullulansSM-2001 andDendropanax morbiferaleaf extracts in ovariectomized rats. J Food Biochem 2018. [DOI: 10.1111/jfbc.12548] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Affiliation(s)
- Chang-Soo Cho
- Hurim Hwangchil Co., Ltd., 907-11, Gyeongseo-dearo, Hoengcheon-myeon; Hadong-gun Gyeongsangnam-do 52320 Republic of Korea
| | - Hye-Seong Jeong
- Hurim Hwangchil Co., Ltd., 907-11, Gyeongseo-dearo, Hoengcheon-myeon; Hadong-gun Gyeongsangnam-do 52320 Republic of Korea
| | - In-Young Kim
- Hurim Hwangchil Co., Ltd., 907-11, Gyeongseo-dearo, Hoengcheon-myeon; Hadong-gun Gyeongsangnam-do 52320 Republic of Korea
| | - Go-Woon Jung
- Glucan Corp., #305 Marine Bio-Industry Development Center, 7 Hoenggye-gil; Busan 46048 Republic of Korea
| | - Bon-Hwa Ku
- Glucan Corp., #305 Marine Bio-Industry Development Center, 7 Hoenggye-gil; Busan 46048 Republic of Korea
| | - Dong-Chan Park
- Glucan Corp., #305 Marine Bio-Industry Development Center, 7 Hoenggye-gil; Busan 46048 Republic of Korea
| | - Seung-Bae Moon
- Glucan Corp., #305 Marine Bio-Industry Development Center, 7 Hoenggye-gil; Busan 46048 Republic of Korea
| | - Hyung-Rae Cho
- Glucan Corp., #305 Marine Bio-Industry Development Center, 7 Hoenggye-gil; Busan 46048 Republic of Korea
| | - Sae Kwang Ku
- Department of Anatomy and Histology, College of Korean Medicine; Daegu Haany University, 1, Hanuidae-ro; Gyeongsan-si Gyeongsangbuk-do 38610 Republic of Korea
| | - Jae-Suk Choi
- Major in Food Biotechnology, Division of Bioindustry, College of Medical and Life Sciences; Silla University, 140, Baegyang-daero 700beon-gil; Busan 46958 Republic of Korea
| |
Collapse
|
6
|
Sens C, Huck K, Pettera S, Uebel S, Wabnitz G, Moser M, Nakchbandi IA. Fibronectins containing extradomain A or B enhance osteoblast differentiation via distinct integrins. J Biol Chem 2017; 292:7745-7760. [PMID: 28325836 DOI: 10.1074/jbc.m116.739987] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2016] [Revised: 03/10/2017] [Indexed: 12/16/2022] Open
Abstract
Fibronectin is a multidomain protein secreted by various cell types. It forms a network of fibers within the extracellular matrix and impacts intracellular processes by binding to various molecules, primarily integrin receptors on the cells. Both the presence of several isoforms and the ability of the various domains and isoforms to bind to a variety of integrins result in a wide range of effects. In vivo findings suggest that fibronectin isoforms produced by the osteoblasts enhance their differentiation. Here we report that the isoform characterized by the presence of extradomain A activates α4β1 integrin and augments osteoblast differentiation. In addition, the isoform containing extradomain B enhances the binding of fibronectin through the RGD sequence to β3-containing integrin, resulting in increased mineralization by and differentiation of osteoblasts. Our study thus reveals novel functions for two fibronectin isoforms and the mediating receptors in osteoblast differentiation.
Collapse
Affiliation(s)
- Carla Sens
- From the Max-Planck Institute of Biochemistry, 82152 Martinsried and.,the Institute of Immunology, University of Heidelberg, 69120 Heidelberg, Germany
| | - Katrin Huck
- From the Max-Planck Institute of Biochemistry, 82152 Martinsried and.,the Institute of Immunology, University of Heidelberg, 69120 Heidelberg, Germany
| | - Stefan Pettera
- From the Max-Planck Institute of Biochemistry, 82152 Martinsried and
| | - Stephan Uebel
- From the Max-Planck Institute of Biochemistry, 82152 Martinsried and
| | - Guido Wabnitz
- the Institute of Immunology, University of Heidelberg, 69120 Heidelberg, Germany
| | - Markus Moser
- From the Max-Planck Institute of Biochemistry, 82152 Martinsried and
| | - Inaam A Nakchbandi
- From the Max-Planck Institute of Biochemistry, 82152 Martinsried and .,the Institute of Immunology, University of Heidelberg, 69120 Heidelberg, Germany
| |
Collapse
|
7
|
Anti-climacterium effects of pomegranate concentrated solutions in ovariectomized ddY mice. Exp Ther Med 2017; 13:1249-1266. [PMID: 28413464 DOI: 10.3892/etm.2017.4109] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2015] [Accepted: 10/05/2016] [Indexed: 12/14/2022] Open
Abstract
In the present study, the complex anti-climacterium potential of standardized pomegranate concentrated solution (PCS) was investigated using bilateral ovariectomy (OVX) female ddY mice. Changes in body weight and gain during experimental periods, food consumption, serum estradiol levels, total body and abdominal fat densities, abdominal fat pads, and uterus weights were observed, along with the histopathology of abdominal fat pads and uterus for anti-obesity and estrogenic effects. In addition, liver weights, serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) levels, and histopathological inspections were performed to explore the hepato-protective effects. Serum total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein, and triglyceride (TG) levels were monitored for hypolipidemic effects with total body and femur mean bone mineral density (BMD), right femur wet, dry and ash weights, strength, serum osteocalcin, bone-specific alkaline phosphatase (bALP) contents, and histological and histomorphometrical analyses for anti-osteoporosis activity. As a result of OVX, notable increases in body weight and gains, food consumption, abdominal fat mass densities, weights of abdominal fat pads deposited in the abdominal cavity, and serum AST, ALT, TC, LDL, TG, and osteocalcin levels were observed, along with decreases in the uterus, liver, and femur weights, mean total body and femur BMD, femur strength, serum bALP, and estradiol levels. In addition, marked hypertrophic alterations in adipocytes located in the deposited abdominal fat pads, liver steatosis, uterine disused atrophic changes, and decreases in bone mass and structures of the femur were also observed in OVX control mice with significant increases in bone resorption markers based on histopathological and histomorphometrical analysis. However, these estrogen-deficient climacterium symptoms were significantly (P<0.05 or P<0.01) inhibited after 84 days of continuous treatment with estradiol and PCS (1, 2 and 4 ml/kg), respectively. The present results suggested that PCS was able to effectively inhibit or refine the climacterium symptoms, including obesity, hyperlipidemia, hepatic steatosis, and osteoporosis, induced by OVX in ddY mice.
Collapse
|
8
|
Park D, Park CW, Choi Y, Lin J, Seo DH, Kim HS, Lee SY, Kang IC. A novel small-molecule PPI inhibitor targeting integrin αvβ3-osteopontin interface blocks bone resorption in vitro and prevents bone loss in mice. Biomaterials 2016; 98:131-42. [DOI: 10.1016/j.biomaterials.2016.05.007] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2016] [Accepted: 05/02/2016] [Indexed: 01/11/2023]
|
9
|
Selection of the Optimal Herbal Compositions of Red Clover and Pomegranate According to Their Protective Effect against Climacteric Symptoms in Ovariectomized Mice. Nutrients 2016; 8:nu8080447. [PMID: 27455321 PMCID: PMC4997362 DOI: 10.3390/nu8080447] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2015] [Revised: 07/19/2016] [Accepted: 07/21/2016] [Indexed: 02/07/2023] Open
Abstract
This study aimed to ascertain the optimal range of red clover dry extracts (RC) and dried pomegranate concentrate powder (PCP) to induce anti-climacteric effects. Thus, the dose ranges showing protective effect of mixed formulae consisting of RC and PCP were examined in ovariectomized mice. At 28 days after bilateral ovariectomy (OVX), mixed herbal compositions (RC:PCP = 1:1, 1:2, 1:4, 1:8, 2:1, 4:1, and 8:1) were administered orally, at 120 mg/kg once daily for 84 days. We evaluated that RC and PCP mixture attenuate OVX-caused obesity, hyperlipidemia, hepatic steatosis, and osteoporosis. Compared to OVX-induced control mice, body weight and abdominal fat weight in OVX-induced mice were significantly decreased, concomitantly with increase of uterus weight by RC:PCP mixture. Additionally, significant increases in serum estradiol levels were observed in all RC:PCP-treated mice. RC:PCP mixture also showed protective effect against OVX-induced hyperlipidemia, hepatic steatosis. Total body and femur mean bone mineral density (BMD), osteocalcin, bALP contents were effectively increased by RC:PCP mixture. Taken together, RC:PCP mixture (2:1, 1:1, and 4:1) has remarkable protective effects against the changes induced by OVX. In particular, RC:PCP mixture (2:1) shows the strongest effect and may be considered as a potential protective agent against climacteric symptoms.
Collapse
|
10
|
Rehm S, Thomas RA, Smith KS, Mirabile RC, Gales TL, Eustis SL, Boyce RW. Novel Vascular Lesions in Mice Given a Non-Peptide Vitronectin Receptor Antagonist. Toxicol Pathol 2016; 35:958-71. [DOI: 10.1080/01926230701748230] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Novel vascular lesions were observed in mice given an αvβ3, αvβ5 receptor antagonist (SB-273005) for up to 3 months. Vascular smooth muscle cell (VSMC) necrosis was observed in aorta and renal hilar arteries approximately 6 hours after dosing followed by loss of VSMC, adaptive medial thickening by VSMC hypertrophy and deposition of PAS-positive matrix and collagen. Renal hilar and arcuate arteries developed delayed and transient fibrinoid necrosis and inflammation. Vascular regeneration was not evident following drug-withdrawal after 3 days of dosing. Vascular lesions were associated with necrosis, regeneration and fibrosis of heart, kidney and spleen consistent with initial ischemic injury followed by tissue repair. VSMC toxicity was likely not related to integrin antagonism because lesions were not observed with related compounds and no vascular changes were observed in other preclinical species. In vitro studies failed to demonstrate a direct toxic effect of SB-273005 on VSMC or unique species sensitivity of murine VSMC. In conclusion, SB-273005 caused VSMC necrosis in aorta and renal arteries of mice. Lesions did not progress or recover, but there was medial hypertrophic adaptation even with continued dosing. This is considered direct species-specific VSMC toxicity of unknown mechanism and unrelated to vitronectin receptor antagonism.
Collapse
Affiliation(s)
- Sabine Rehm
- GlaxoSmithKline, 709 Swedeland Rd, King of Prussia, PA 19406, USA
| | | | - Kim S. Smith
- GlaxoSmithKline, 709 Swedeland Rd, King of Prussia, PA 19406, USA
| | | | - Tracy L. Gales
- GlaxoSmithKline, 709 Swedeland Rd, King of Prussia, PA 19406, USA
| | | | - Rogely W. Boyce
- GlaxoSmithKline, 709 Swedeland Rd, King of Prussia, PA 19406, USA
| |
Collapse
|
11
|
Gentile MA, Soung DY, Horrell C, Samadfam R, Drissi H, Duong LT. Increased fracture callus mineralization and strength in cathepsin K knockout mice. Bone 2014; 66:72-81. [PMID: 24928497 DOI: 10.1016/j.bone.2014.04.032] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2013] [Revised: 03/21/2014] [Accepted: 04/14/2014] [Indexed: 01/06/2023]
Abstract
Cathepsin K (CatK) is a cysteine protease, expressed predominantly in osteoclasts (OC) which degrades demineralized bone matrix. Novel selective inhibitors of CatK are currently being developed for the treatment of postmenopausal osteoporosis. Pharmacological inhibition of CatK reduces OC resorption activity while preserving bone formation in preclinical models. Disruption of the CatK gene in mice also results in high bone mass due to impaired bone resorption and elevated formation. Here, we assessed mid-shaft femoral fracture healing in 8-10week old CatK knock-out (KO) versus wild type (WT) mice. Fracture healing and callus formation were determined in vivo weekly via X-ray, and ex vivo at days 14, 18, 28 and 42 post-fracture by radiographic scoring, micro-computed tomography (μCT), histomorphometry and terminal mechanical four point bend strength testing. Radiological evaluation indicated accelerated bone healing and remodeling for CatK KO animals based on increased total radiographic scores that included callus opacity and bridging at days 28 and 42 post-fracture. Micro-CT based total callus volume was similar in CatK KO and WT mice at day 14. Callus size in CatK KO mice was 25% smaller than that in WT mice at day 18, statistically significant by day 28 and exhibited significantly higher mineralized tissue volume and volumetric BMD as compared to WT by day 18 onward. Osteoclast surface and osteoid surface trended higher in CatK KO calluses at all time-points and osteoblast number was also significantly increased at day 28. Increased CatK KO callus mineral density was reflected in significant increases in peak load and stiffness over WT at day 42 post-fracture. Regression analysis indicated a positive correlation (r=0.8671; p<0.001) between callus BMC and peak load indicating normal mineral properties in CatK KO calluses. Taken together, gene deletion of cathepsin K in mice accelerated callus size resolution, significantly increased callus mineralized mass, and improved mechanical strength as compared to wild type mice.
Collapse
Affiliation(s)
- Michael A Gentile
- Bone Biology Group, Merck Research Laboratories, West Point, PA, USA
| | - Do Y Soung
- New England Musculoskeletal Institute, University of Connecticut Health Center, Farmington, CT, USA
| | - Carlyle Horrell
- Bone Biology Group, Merck Research Laboratories, West Point, PA, USA
| | - Rana Samadfam
- Charles River Laboratories, Preclinical Services, Montreal, Quebec, Canada
| | - Hicham Drissi
- New England Musculoskeletal Institute, University of Connecticut Health Center, Farmington, CT, USA
| | - Le T Duong
- Bone Biology Group, Merck Research Laboratories, West Point, PA, USA.
| |
Collapse
|
12
|
Schmidt A, Meissner RS, Gentile MA, Chisamore MJ, Opas EE, Scafonas A, Cusick TE, Gambone C, Pennypacker B, Hodor P, Perkins JJ, Bai C, Ferraro D, Bettoun DJ, Wilkinson HA, Alves SE, Flores O, Ray WJ. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells. J Steroid Biochem Mol Biol 2014; 143:29-39. [PMID: 24565564 DOI: 10.1016/j.jsbmb.2014.02.005] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/23/2013] [Revised: 02/10/2014] [Accepted: 02/14/2014] [Indexed: 11/26/2022]
Abstract
Prostate cancer (PCa) initially responds to inhibition of androgen receptor (AR) signaling, but inevitably progresses to hormone ablation-resistant disease. Much effort is focused on optimizing this androgen deprivation strategy by improving hormone depletion and AR antagonism. However we found that bicalutamide, a clinically used antiandrogen, actually resembles a selective AR modulator (SARM), as it partially regulates 24% of endogenously 5α-dihydrotestosterone (DHT)-responsive genes in AR(+) MDA-MB-453 breast cancer cells. These data suggested that passive blocking of all AR functions is not required for PCa therapy. Hence, we adopted an active strategy that calls for the development of novel SARMs, which induce a unique gene expression profile that is intolerable to PCa cells. Therefore, we screened 3000 SARMs for the ability to arrest the androgen-independent growth of AR(+) 22Rv1 and LNCaP PCa cells but not AR(-) PC3 or DU145 cells. We identified only one such compound; the 4-aza-steroid, MK-4541, a potent and selective SARM. MK-4541 induces caspase-3 activity and cell death in both androgen-independent, AR(+) PCa cell lines but spares AR(-) cells or AR(+) non-PCa cells. This activity correlates with its promoter context- and cell-type dependent transcriptional effects. In rats, MK-4541 inhibits the trophic effects of DHT on the prostate, but not the levator ani muscle, and triggers an anabolic response in the periosteal compartment of bone. Therefore, MK-4541 has the potential to effectively manage prostatic hypertrophic diseases owing to its antitumor SARM-like mechanism, while simultaneously maintaining the anabolic benefits of natural androgens.
Collapse
MESH Headings
- Anabolic Agents/chemistry
- Anabolic Agents/pharmacology
- Androgen Receptor Antagonists/pharmacology
- Androgens/pharmacology
- Animals
- Apoptosis/drug effects
- Azasteroids/chemistry
- Azasteroids/pharmacology
- Blotting, Western
- Breast Neoplasms/drug therapy
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- Carbamates/chemistry
- Carbamates/pharmacology
- Cell Proliferation/drug effects
- Combinatorial Chemistry Techniques
- Female
- Humans
- Male
- Mice
- Mice, Inbred C57BL
- Prostatic Neoplasms/drug therapy
- Prostatic Neoplasms/metabolism
- Prostatic Neoplasms/pathology
- Prostatic Neoplasms, Castration-Resistant/drug therapy
- Prostatic Neoplasms, Castration-Resistant/metabolism
- Prostatic Neoplasms, Castration-Resistant/pathology
- RNA, Messenger/genetics
- Rats
- Rats, Sprague-Dawley
- Real-Time Polymerase Chain Reaction
- Receptors, Androgen/chemistry
- Receptors, Androgen/metabolism
- Reverse Transcriptase Polymerase Chain Reaction
- Tumor Cells, Cultured
Collapse
Affiliation(s)
- Azriel Schmidt
- Departments of Molecular Endocrinology, West Point, PA 19486, USA.
| | | | | | | | - Evan E Opas
- Departments of Molecular Endocrinology, West Point, PA 19486, USA
| | - Angela Scafonas
- Departments of Molecular Endocrinology, West Point, PA 19486, USA
| | - Tara E Cusick
- Departments of Molecular Endocrinology, West Point, PA 19486, USA; Departments of Medicinal Chemistry, West Point, PA 19486, USA; Departments of Molecular Profiling Merck & Co., West Point, PA 19486, USA
| | - Carlo Gambone
- Departments of Molecular Endocrinology, West Point, PA 19486, USA
| | | | - Paul Hodor
- Departments of Molecular Profiling Merck & Co., West Point, PA 19486, USA
| | - James J Perkins
- Departments of Medicinal Chemistry, West Point, PA 19486, USA
| | - Chang Bai
- Departments of Molecular Endocrinology, West Point, PA 19486, USA
| | - Damien Ferraro
- Departments of Molecular Endocrinology, West Point, PA 19486, USA
| | - David J Bettoun
- Departments of Molecular Endocrinology, West Point, PA 19486, USA
| | | | - Stephen E Alves
- Departments of Molecular Endocrinology, West Point, PA 19486, USA
| | - Osvaldo Flores
- Departments of Molecular Endocrinology, West Point, PA 19486, USA
| | - William J Ray
- Departments of Molecular Endocrinology, West Point, PA 19486, USA.
| |
Collapse
|
13
|
Choi JS, Kim JW, Kim KY, Cho HR, Choi IS, Ku SK. Antiosteoporotic effects of Polycan in combination with calcium lactate-gluconate in ovariectomized rats. Exp Ther Med 2014; 8:957-967. [PMID: 25120630 PMCID: PMC4113539 DOI: 10.3892/etm.2014.1793] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2013] [Accepted: 02/26/2014] [Indexed: 12/19/2022] Open
Abstract
The aim of the present study was to investigate the optimum composition of Polycan (β-glucan complex) and calcium lactate-gluconate (CaLG) that exhibited the most beneficial effects in ovariectomy (OVX)-induced osteoporotic rats. Polycan and CaLG single formulas (100 mg/kg each), and three doses (50, 100 and 200 mg/kg) of three mixed formulas [polycan:CaLG (PCLG)=1:99, 5:95 and 10:90] were orally administered once a day for 84 days. The effects of the test materials were compared with those of a risedronate sodium-treated group. OVX resulted in an increase in body weight, decreased bone formation, elevated serum osteocalcin levels and urine deoxypyridinoline/creatinine ratio, as well as decreased serum bone-specific alkaline phosphatase levels, femur indices, bone mineral content, bone mineral density and failure load. However, these OVX-induced osteoporotic changes markedly decreased following the administration of the test materials. Continuous oral treatment of Polycan or CaLG single formulas and the PCLG mixed formulas preserved bone mass and strength. The PCLG 10:90 mixed formula exhibited the most favorable synergistic antiosteoporotic effects in the OVX-induced osteoporotic rats as compared with equal doses of the Polycan or CaLG single formulas.
Collapse
Affiliation(s)
- Jae-Suk Choi
- RIS Center, Industry-Academic Cooperation Foundation, Silla University, Busan 702-701, Republic of Korea
| | - Joo Wan Kim
- Glucan Corporation Research Institute, Marine Bio-Industry Development Center, Busan 619-912, Republic of Korea
| | - Ki Young Kim
- Glucan Corporation Research Institute, Marine Bio-Industry Development Center, Busan 619-912, Republic of Korea
| | - Hyung-Rae Cho
- Glucan Corporation Research Institute, Marine Bio-Industry Development Center, Busan 619-912, Republic of Korea
| | - In Soon Choi
- RIS Center, Industry-Academic Cooperation Foundation, Silla University, Busan 702-701, Republic of Korea ; Department of Biological Science, Silla University, Busan 702-701, Republic of Korea
| | - Sae Kwang Ku
- Department of Anatomy and Histology, College of Oriental Medicine, Daegu Haany University, Gyeongsan 712-715, Republic of Korea
| |
Collapse
|
14
|
Development and validation of competition binding assays for affinity to the extracellular matrix receptors, α(v)β(3) and α(IIb)β(3) integrin. Anal Biochem 2012; 423:70-7. [PMID: 22285979 DOI: 10.1016/j.ab.2011.12.046] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2011] [Revised: 12/23/2011] [Accepted: 12/29/2011] [Indexed: 01/16/2023]
Abstract
The RGD (Arg-Gly-Asp) binding integrins α(v)β(3) and α(IIb)β(3) are integral components of various pathological and physiological processes, including tumor angiogenesis, osteoclast function, and thrombus formation. Because of this, there is interest in identifying novel compounds and proteins binding to these receptors as well as investigating the mechanism of these interactions. In this article, we describe the development and validation of competition binding assays for determining the affinity of test compounds to α(v)β(3) and α(IIb)β(3) integrin. Assays were successfully developed for each receptor, and the affinity of known compounds was comparable to published results. However, the inability of binding between α(IIb)β(3) integrin and the labeled echistatin protein ligand to reach equilibrium resulted in an assay that did not meet the assumptions of the competition binding model. Nevertheless, there was good agreement between this assay and known literature values, and intra- and interassay variability was acceptable. Binding by conformation-specific antibodies provided evidence that solid-phase bound α(IIb)β(3) receptor was in an activated conformation. This study also demonstrated that current models and methods for determining receptor affinity are simplistic and fail to account for common receptor-ligand interactions such as nondissociable interactions and varying receptor activation states.
Collapse
|
15
|
Levaot N, Simoncic PD, Dimitriou ID, Scotter A, La Rose J, Ng AHM, Willett TL, Wang CJ, Janmohamed S, Grynpas M, Reichenberger E, Rottapel R. 3BP2-deficient mice are osteoporotic with impaired osteoblast and osteoclast functions. J Clin Invest 2011; 121:3244-57. [PMID: 21765218 DOI: 10.1172/jci45843] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2010] [Accepted: 06/01/2011] [Indexed: 12/29/2022] Open
Abstract
A fine balance between bone resorption by osteoclasts and bone formation by osteoblasts maintains bone homeostasis. In patients with cherubism, gain-of-function mutations in 3BP2, which is encoded by SH3-domain binding protein 2 (SH3BP2), cause cystic lesions with activated osteoclasts that lead to craniofacial abnormalities. However, little is known about the function of wild-type 3BP2 in regulating bone homeostasis. Here we have shown that 3BP2 is required for the normal function of both osteoblasts and osteoclasts. Initial analysis showed that Sh3bp2-/-mice developed osteoporosis as a result of reduced bone formation despite the fact that bone resorption was impaired. We demonstrated using reciprocal bone marrow chimeras, a cell-intrinsic defect of the osteoblast and osteoclast compartments in vivo. Further, Sh3bp2-/- osteoblasts failed to mature and form mineralized nodules in vitro, while Sh3bp2-/- osteoclasts spread poorly and were unable to effectively degrade dentine matrix in vitro. Finally, we showed that 3BP2 was required for Abl activation in osteoblasts and Src activation in osteoclasts, and demonstrated that the in vitro defect of each cell type was restored by the respective expression of activated forms of these kinases. These findings reveal an unanticipated role for the 3BP2 adapter protein in osteoblast function and in coordinating bone homeostatic signals in both osteoclast and osteoblast lineages.
Collapse
Affiliation(s)
- Noam Levaot
- Campbell Family Cancer Research Institute, Ontario Cancer Institute, Princess Margaret Hospital, University Health Network, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
Integrins are heterodimeric, transmembrane receptors that function as mechanosensors, adhesion molecules and signal transduction platforms in a multitude of biological processes. As such, integrins are central to the etiology and pathology of many disease states. Therefore, pharmacological inhibition of integrins is of great interest for the treatment and prevention of disease. In the last two decades several integrin-targeted drugs have made their way into clinical use, many others are in clinical trials and still more are showing promise as they advance through preclinical development. Herein, this review examines and evaluates the various drugs and compounds targeting integrins and the disease states in which they are implicated.
Collapse
|
17
|
Liu J, Arends R, Martens A, den Brok-Bardoel MHC, Scheepers MGH, van Blitterswijk CA, de Boer J. Noninvasive imaging of bone-specific collagen I expression in a luciferase transgenic mouse model. Tissue Eng Part C Methods 2010; 16:1297-304. [PMID: 20218816 DOI: 10.1089/ten.tec.2009.0594] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Luciferase transgenic mice are a very promising tool for noninvasive, quantitative, and longitudinal evaluation of gene expression. The aim of this study was to validate the Col(I)-Luc transgenic mouse model in which the luciferase gene is driven by bone-specific regulatory elements from the mouse collagen α1(I) gene for bioluminescent imaging of bone development and remodeling. We observed strong luciferase activity in skeletal tissues of Col(I)-Luc mice, and observed that the light intensity declined with postnatal bone development. Luciferase activity was enhanced in a tail bone repair model and we were able to monitor the process of ectopic bone formation induced by recombinant human bone morphogenetic protein 2 using bioluminescent imaging. We conclude that Col(I)-Luc transgenic mice can be applied in the field of bone tissue engineering for monitoring bone repair processes and for investigating osteoinductive molecules or scaffolds.
Collapse
Affiliation(s)
- Jun Liu
- Department of Tissue Regeneration, MIRA Research Institute, University of Twente, Enschede, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
18
|
Allen JG, Fotsch C, Babij P. Emerging Targets in Osteoporosis Disease Modification. J Med Chem 2010; 53:4332-53. [PMID: 20218623 DOI: 10.1021/jm9018756] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Affiliation(s)
- John G. Allen
- Chemistry Research and Discovery, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Christopher Fotsch
- Chemistry Research and Discovery, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| | - Philip Babij
- Metabolic Disorders, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320
| |
Collapse
|
19
|
Schmidt A, Harada SI, Kimmel DB, Bai C, Chen F, Rutledge SJ, Vogel RL, Scafonas A, Gentile MA, Nantermet PV, McElwee-Witmer S, Pennypacker B, Masarachia P, Sahoo SP, Kim Y, Meissner RS, Hartman GD, Duggan ME, Rodan GA, Towler DA, Ray WJ. Identification of anabolic selective androgen receptor modulators with reduced activities in reproductive tissues and sebaceous glands. J Biol Chem 2009; 284:36367-36376. [PMID: 19846549 DOI: 10.1074/jbc.m109.049734] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Androgen replacement therapy is a promising strategy for the treatment of frailty; however, androgens pose risks for unwanted effects including virilization and hypertrophy of reproductive organs. Selective Androgen Receptor Modulators (SARMs) retain the anabolic properties of androgens in bone and muscle while having reduced effects in other tissues. We describe two structurally similar 4-aza-steroidal androgen receptor (AR) ligands, Cl-4AS-1, a full agonist, and TFM-4AS-1, which is a SARM. TFM-4AS-1 is a potent AR ligand (IC(50), 38 nm) that partially activates an AR-dependent MMTV promoter (55% of maximal response) while antagonizing the N-terminal/C-terminal interaction within AR that is required for full receptor activation. Microarray analyses of MDA-MB-453 cells show that whereas Cl-4AS-1 behaves like 5alpha-dihydrotestosterone (DHT), TFM-4AS-1 acts as a gene-selective agonist, inducing some genes as effectively as DHT and others to a lesser extent or not at all. This gene-selective agonism manifests as tissue-selectivity: in ovariectomized rats, Cl-4AS-1 mimics DHT while TFM-4AS-1 promotes the accrual of bone and muscle mass while having reduced effects on reproductive organs and sebaceous glands. Moreover, TFM-4AS-1 does not promote prostate growth and antagonizes DHT in seminal vesicles. To confirm that the biochemical properties of TFM-4AS-1 confer tissue selectivity, we identified a structurally unrelated compound, FTBU-1, with partial agonist activity coupled with antagonism of the N-terminal/C-terminal interaction and found that it also behaves as a SARM. TFM-4AS-1 and FTBU-1 represent two new classes of SARMs and will allow for comparative studies aimed at understanding the biophysical and physiological basis of tissue-selective effects of nuclear receptor ligands.
Collapse
Affiliation(s)
- Azriel Schmidt
- Department of Molecular Endocrinology/Bone Biology, Merck Research Laboratories, West Point, Pennsylvania 19486.
| | - Shun-Ichi Harada
- Department of Molecular Endocrinology/Bone Biology, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Donald B Kimmel
- Department of Molecular Endocrinology/Bone Biology, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Chang Bai
- Department of Molecular Endocrinology/Bone Biology, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Fang Chen
- Department of Molecular Endocrinology/Bone Biology, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Su Jane Rutledge
- Department of Molecular Endocrinology/Bone Biology, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Robert L Vogel
- Department of Molecular Endocrinology/Bone Biology, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Angela Scafonas
- Department of Molecular Endocrinology/Bone Biology, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Michael A Gentile
- Department of Molecular Endocrinology/Bone Biology, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Pascale V Nantermet
- Department of Molecular Endocrinology/Bone Biology, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Sheila McElwee-Witmer
- Department of Molecular Endocrinology/Bone Biology, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Brenda Pennypacker
- Department of Molecular Endocrinology/Bone Biology, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Patricia Masarachia
- Department of Molecular Endocrinology/Bone Biology, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Soumya P Sahoo
- Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, New Jersey 07065
| | - Yuntae Kim
- Department of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Robert S Meissner
- Department of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - George D Hartman
- Department of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Mark E Duggan
- Department of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Gideon A Rodan
- Department of Molecular Endocrinology/Bone Biology, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - Dwight A Towler
- Department of Molecular Endocrinology/Bone Biology, Merck Research Laboratories, West Point, Pennsylvania 19486
| | - William J Ray
- Department of Molecular Endocrinology/Bone Biology, Merck Research Laboratories, West Point, Pennsylvania 19486
| |
Collapse
|
20
|
Affiliation(s)
- P J Marie
- Laboratory of Osteoblast Biology and Pathology, INSERM U606 and University Paris 7, Hopital Lariboisiere, 2 rue Ambroise Pare, 75475 Paris, Cedex 10, France.
| |
Collapse
|
21
|
Holliday LS, Ostrov DA, Wronski TJ, Dolce C. Osteoclast polarization and orthodontic tooth movement. Orthod Craniofac Res 2009; 12:105-12. [DOI: 10.1111/j.1601-6343.2009.01443.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
22
|
Otis M, Campbell S, Payet MD, Gallo-Payet N. In adrenal glomerulosa cells, angiotensin II inhibits proliferation by interfering with fibronectin-integrin signaling. Endocrinology 2008; 149:3435-45. [PMID: 18388189 DOI: 10.1210/en.2008-0282] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Angiotensin II (Ang II), through the Ang II type 1 receptor subtype, inhibits basal proliferation of adrenal glomerulosa cells by inducing the disruption of actin stress fiber organization. This effect is observed in cells cultured on plastic or on fibronectin. The aim of the present study was to investigate how Ang II may interfere with extracellular matrix/integrin signaling. In cells treated for 3 d with echistatin (EC) (a snake-venom RGD-containing protein that abolishes fibronectin binding to alpha(5)beta(1) or alpha(v)beta(3) integrins), basal proliferation decreased by 38%, whereas Ang II was unable to abolish basal proliferation. In cells grown on fibronectin, Ang II decreased binding of paxillin to focal adhesions and, similarly to EC, induced a rapid dephosphorylation of paxillin (1 min), followed by an increase after 15 min. Fibronectin enhanced RhoA/B and Rac activation induced by Ang II, an effect abolished by EC. Under basal conditions, paxillin was more readily associated with RhoA/B than with Rac. Stimulation with Ang II induced a transient decrease in RhoA/B-associated paxillin (after 5 min), with a return to basal levels after 10 min, while increasing Rac-associated paxillin. Finally, results reveal that glomerulosa cells are able to synthesize and secrete fibronectin, a process by which cells can stimulate their own proliferative activity when cultured on plastic. Together, these results suggest that Ang II acts at the level of integrin-paxillin complexes to disrupt the well- developed microfilament network, a condition necessary for the inhibition of cell proliferation and initiation of steroidogenesis.
Collapse
Affiliation(s)
- Mélissa Otis
- Service of Endocrinology, Faculty of Medicine, Université de Sherbrooke, 3001 12th Avenue North, Sherbrooke, Quebec, Canada
| | | | | | | |
Collapse
|
23
|
Crotti TN, Sharma SM, Fleming JD, Flannery MR, Ostrowski MC, Goldring SR, McHugh KP. PU.1 and NFATc1 mediate osteoclastic induction of the mouse beta3 integrin promoter. J Cell Physiol 2008; 215:636-44. [PMID: 18288635 DOI: 10.1002/jcp.21344] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Expression of the alpha(v)beta(3) integrin is required for normal osteoclast function. We previously showed that an evolutionary conserved NFATc1 binding site is required for RANKL induction and NFATc1 transactivation of the human beta(3) promoter. The mechanism conferring specificity for RANKL induction and NFATc1 transduction of the beta(3) gene in osteoclast differentiation is unclear since NFATc1 is expressed and activated in numerous cell types that do not express the beta(3) gene. PU.1 is an ETS family transcription factor in myeloid cells associated with expression of various osteoclast genes. The present study investigates the role of NFATc1 in concert with PU.1 in osteoclast-specific transcription of the mouse beta(3) integrin gene. The mouse beta(3) promoter was transactivated by NFATc1 in RAW264.7 cells and deletion or mutation of either of the conserved NFAT and PU.1 binding sites abrogated transactivation. NFATc1 transactivation of the mouse beta(3) promoter was specifically dependent on co-transfected PU.1 in HEK293 cells, to the exclusion of other ETS family members. Direct binding of NFATc1 and PU.1 to their cognate sequences was demonstrated by EMSA and NFATc1 and PU.1 occupy their cognate sites in RANKL-treated mouse marrow precursors in chromatin immuno-precipitation (ChIP) assays. TAT-mediated transduction with dominant-negative NFATc1 dose-dependently blocked endogenous expression of the mouse beta(3) integrin and the formation of TRAP positive multinucleated cells in RANKL-treated mouse macrophages. These data provide evidence that NFATc1, in concert with PU.1, are involved in regulation of beta(3) integrin expression during osteoclast differentiation and suggest that PU.1 confers specificity to the NFATc1 response to macrophage lineage cells.
Collapse
Affiliation(s)
- Tania N Crotti
- The New England Baptist Bone and Joint Institute, Department of Rheumatology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, Massachusetts 02115, USA.
| | | | | | | | | | | | | |
Collapse
|
24
|
Perrini S, Natalicchio A, Laviola L, Cignarelli A, Melchiorre M, De Stefano F, Caccioppoli C, Leonardini A, Martemucci S, Belsanti G, Miccoli S, Ciampolillo A, Corrado A, Cantatore FP, Giorgino R, Giorgino F. Abnormalities of insulin-like growth factor-I signaling and impaired cell proliferation in osteoblasts from subjects with osteoporosis. Endocrinology 2008; 149:1302-13. [PMID: 18079194 DOI: 10.1210/en.2007-1349] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
IGF-I regulates bone acquisition and maintenance, even though the cellular targets and signaling pathways responsible for its action in human bone cells are poorly understood. Whether abnormalities in IGF-I action and signaling occur in human osteoblasts under conditions of net bone loss has not been determined. Herein we carried out a comparative analysis of IGF-I signaling in primary cultures of human osteoblasts from osteoporotic and control donors. In comparison with control cells, osteoporotic osteoblasts showed increased tyrosine phosphorylation of the IGF-I receptor in the basal state and blunted stimulation of receptor phosphorylation by IGF-I. Augmentation of basal IGF-I receptor phosphorylation was associated with coordinate increases in basal tyrosine phosphorylation of insulin receptor substrate (IRS)-2 and activation of Erk, which were also minimally responsive to IGF-I stimulation. By contrast, phosphorylation levels of IRS-1, Akt, and glycogen synthase kinase-3 were similar in the basal state in control and osteoporotic osteoblasts and showed marked increases after IGF-I stimulation in both cell populations, even though these responses were significantly lower in the osteoporotic osteoblasts. The IGF-I signaling abnormalities in osteoporotic osteoblasts were associated with reduced DNA synthesis both under basal conditions and after stimulation with IGF-I. Interestingly, treatment of the osteoporotic osteoblasts with the MAPK kinase inhibitor PD098059 reduced the elevated levels of Erk phosphorylation and increased basal DNA synthesis. Collectively, our data show that altered osteoblast proliferation in human osteoporosis may result from dysregulation of IGF-I receptor signaling, including constitutive activation of the IRS-2/Erk signaling pathway, which becomes unresponsive to IGF-I, and defective induction of the IRS-1/Akt signaling pathway.
Collapse
Affiliation(s)
- Sebastio Perrini
- Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, and Metabolic Diseases, University of Bari, Piazza Giulio Cesare, 11, I-70124 Bari, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Ding DC, Shyu WC, Chiang MF, Lin SZ, Chang YC, Wang HJ, Su CY, Li H. Enhancement of neuroplasticity through upregulation of β1-integrin in human umbilical cord-derived stromal cell implanted stroke model. Neurobiol Dis 2007; 27:339-53. [PMID: 17651977 DOI: 10.1016/j.nbd.2007.06.010] [Citation(s) in RCA: 168] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2007] [Revised: 05/03/2007] [Accepted: 06/04/2007] [Indexed: 01/10/2023] Open
Abstract
Neuroplasticity subsequent to functional angiogenesis is an important goal for cell-based therapy of ischemic neural tissues. At present, the cellular and molecular mechanisms involved are still not well understood. In this study, we isolated mesenchymal stem cells (MSCs) from Wharton's jelly (WJ) to obtain clonally expanded human umbilical cord-derived mesenchymal stem cells (HUCMSCs) with multilineage differentiation potential. Experimental rats receiving intracerebral HUCMSC transplantation showed significantly improved neurological function compared to vehicle-treated control rats. Cortical neuronal activity, as evaluated by proton MR spectroscopy (1H-MRS), also increased considerably in the transplantation group. Transplanted HUCMSCs migrated towards the ischemic boundary zone and differentiated into glial, neuronal, doublecortin+, CXCR4+, and vascular endothelial cells to enhance neuroplasticity in the ischemic brain. In addition, HUCMSC transplantation promoted the formation of new vessels to increase local cortical blood flow in the ischemic hemisphere. Modulation by stem cell-derived macrophage/microglial interactions, and increased beta1-integrin expression, might enhance this angiogenic architecture within the ischemic brain. Inhibition of beta1-integrin expression blocked local angiogenesis and reduced recovery from neurological deficit. In addition, significantly increased modulation of neurotrophic factor expression was also found in the HUCMSC transplantation group. In summary, regulation of beta1-integrin expression plays a critical role in the plasticity of the ischemic brain after the implantation of HUCMSCs.
Collapse
Affiliation(s)
- Dah-Ching Ding
- Graduate Institute of Medical Science, School of Medicine, Buddhist Tzu Chi General Hospital, Tzu-Chi University, Department of Obstetrics and Gynecology, Hualien, Taiwan 970
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Nakamura I, Duong LT, Rodan SB, Rodan GA. Involvement of alpha(v)beta3 integrins in osteoclast function. J Bone Miner Metab 2007; 25:337-44. [PMID: 17968485 DOI: 10.1007/s00774-007-0773-9] [Citation(s) in RCA: 154] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/08/2007] [Accepted: 05/01/2007] [Indexed: 11/26/2022]
Abstract
Integrins are heterodimeric adhesion receptors that mediate cell-matrix interaction. Osteoclast exhibits high expression of the alpha(v)beta(3) integrin, which binds to a variety of extracellular matrix proteins including vitronectin, osteopontin, and bone sialoprotein. Arg-Gly-Asp (RGD)-containing peptides, RGD-mimetics, and blocking antibodies to alpha(v)beta(3) integrin were shown to inhibit bone resorption in vitro and in vivo, suggesting that this integrin may play an important role in regulating osteoclast function. Several lines of evidence have demonstrated that a number of signaling molecules are involved in the alpha(v)beta(3) integrin-dependent signaling pathway, including c-Src, Pyk2, c-Cbl, and p130(Cas). In this article, we review the history of "alpha(v)beta(3) integrin and osteoclasts" and discuss the involvement of alpha(v)beta(3) integrins in osteoclast function at tissue, cellular, and molecular levels. A better understanding of the role of alpha(v)beta(3) integrin in osteoclastic bone resorption would provide opportunities for developing new therapeutics to treat human bone diseases, including rheumatoid arthritis, osteoporosis, and periodontal disease.
Collapse
Affiliation(s)
- Ichiro Nakamura
- Department of Rheumatology, Yugawara Kosei-nenkin Hospital, 438 Miyakami, Yugawara, Ashigara-shimo, Kanagawa 259-0314, Japan.
| | | | | | | |
Collapse
|
27
|
Dayam R, Aiello F, Deng J, Wu Y, Garofalo A, Chen X, Neamati N. Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents. J Med Chem 2006; 49:4526-34. [PMID: 16854058 DOI: 10.1021/jm051296s] [Citation(s) in RCA: 99] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Integrin alphavbeta3 has been implicated in multiple aspects of tumor progression and metastasis. Many tumors have high expression of alphavbeta3 that correlates with tumor progression. Therefore, alphavbeta3 receptor is an excellent target for drug design and delivery. We have discovered a series of novel alphavbeta3 antagonists utilizing common feature pharmacophore models. Upon validation using a database of known alphavbeta3 receptor antagonists, a highly discriminative pharmacophore model was used as a 3D query. A search of a database of 600 000 compounds using the pharmacophore Hypo5 yielded 832 compounds. On the basis of structural novelty, 29 compounds were tested in alphavbeta3 receptor specific binding assay and four compounds showed excellent binding affinity. A limited SAR analysis on the active compound 26 resulted in the discovery of two compounds with nanomolar to subnanomolar binding affinity. These small-molecule compounds could be conjugated to paclitaxel for selective delivery to alphavbeta3 positive metastatic cancer cells.
Collapse
Affiliation(s)
- Raveendra Dayam
- Department of Pharmaceutical Sciences, University of Southern California, Los Angeles, California 90033, USA
| | | | | | | | | | | | | |
Collapse
|
28
|
Abstract
Osteoclasts are multinucleated cells derived from hematopoietic precursors that are primarily responsible for the degradation of mineralized bone during bone development, homeostasis and repair. In various skeletal disorders such as osteoporosis, hypercalcemia of malignancy, tumor metastases and Paget's disease, bone resorption by osteoclasts exceeds bone formation by osteoblasts leading to decreased bone mass, skeletal fragility and bone fracture. The overall rate of osteoclastic bone resorption is regulated either at the level of differentiation of osteoclasts from their monocytic/macrophage precursor pool or through the regulation of key functional proteins whose specific activities in the mature osteoclast control its attachment, migration and resorption. Thus, reducing osteoclast numbers and/or decreasing the bone resorbing activity of osteoclasts are two common therapeutic approaches for the treatment of hyper-resorptive skeletal diseases. In this review, several of the key functional players involved in the regulation of osteoclast activity will be discussed.
Collapse
Affiliation(s)
- Angela Bruzzaniti
- Department of Orthopaedics, Yale University School of Medicine, New Haven, CT 06510, USA.
| | | |
Collapse
|
29
|
Aoki K, Saito H, Itzstein C, Ishiguro M, Shibata T, Blanque R, Mian AH, Takahashi M, Suzuki Y, Yoshimatsu M, Yamaguchi A, Deprez P, Mollat P, Murali R, Ohya K, Horne WC, Baron R. A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. J Clin Invest 2006; 116:1525-34. [PMID: 16680194 PMCID: PMC1448165 DOI: 10.1172/jci22513] [Citation(s) in RCA: 99] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2004] [Accepted: 03/07/2006] [Indexed: 11/17/2022] Open
Abstract
Activating receptor activator of NF-kappaB (RANK) and TNF receptor (TNFR) promote osteoclast differentiation. A critical ligand contact site on the TNFR is partly conserved in RANK. Surface plasmon resonance studies showed that a peptide (WP9QY) that mimics this TNFR contact site and inhibits TNF-alpha-induced activity bound to RANK ligand (RANKL). Changing a single residue predicted to play an important role in the interaction reduced the binding significantly. WP9QY, but not the altered control peptide, inhibited the RANKL-induced activation of RANK-dependent signaling in RAW 264.7 cells but had no effect on M-CSF-induced activation of some of the same signaling events. WP9QY but not the control peptide also prevented RANKL-induced bone resorption and osteoclastogenesis, even when TNFRs were absent or blocked. In vivo, where both RANKL and TNF-alpha promote osteoclastogenesis, osteoclast activity, and bone loss, WP9QY prevented the increased osteoclastogenesis and bone loss induced in mice by ovariectomy or low dietary calcium, in the latter case in both wild-type and TNFR double-knockout mice. These results suggest that a peptide that mimics a TNFR ligand contact site blocks bone resorption by interfering with recruitment and activation of osteoclasts by both RANKL and TNF.
Collapse
MESH Headings
- Amino Acid Sequence
- Animals
- Bone Resorption
- Calcium, Dietary
- Carrier Proteins/chemistry
- Carrier Proteins/metabolism
- Cell Line
- Cells, Cultured
- Female
- Glycoproteins/chemistry
- Glycoproteins/genetics
- Glycoproteins/metabolism
- Lumbar Vertebrae/anatomy & histology
- Lumbar Vertebrae/pathology
- Male
- Membrane Glycoproteins/chemistry
- Membrane Glycoproteins/metabolism
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Models, Molecular
- Molecular Sequence Data
- Osteoclasts/cytology
- Osteoclasts/physiology
- Osteoprotegerin
- Ovariectomy
- Peptides/chemistry
- Peptides/genetics
- Peptides/metabolism
- Protein Conformation
- RANK Ligand
- Receptor Activator of Nuclear Factor-kappa B
- Receptors, Cytoplasmic and Nuclear/chemistry
- Receptors, Cytoplasmic and Nuclear/genetics
- Receptors, Cytoplasmic and Nuclear/metabolism
- Receptors, Tumor Necrosis Factor/chemistry
- Receptors, Tumor Necrosis Factor/genetics
- Receptors, Tumor Necrosis Factor/metabolism
- Sequence Alignment
- Signal Transduction/physiology
- Tumor Necrosis Factor-alpha/metabolism
Collapse
Affiliation(s)
- Kazuhiro Aoki
- Departments of Cell Biology and Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Hard Tissue Engineering, Section of Pharmacology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Suntory Institute for Bioorganic Research, Osaka, Japan.
Department of Pharmacology, Tsurumi University, School of Dental Medicine, Yokohama, Japan.
ProStrakan Pharmaceuticals, Paris, France.
Section of Periodontology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Developmental and Reconstructive Medicine, Orthodontics, Nagasaki University, Nagasaki, Japan.
Department of Oral Restitution, Section of Oral Pathology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | - Hiroaki Saito
- Departments of Cell Biology and Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Hard Tissue Engineering, Section of Pharmacology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Suntory Institute for Bioorganic Research, Osaka, Japan.
Department of Pharmacology, Tsurumi University, School of Dental Medicine, Yokohama, Japan.
ProStrakan Pharmaceuticals, Paris, France.
Section of Periodontology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Developmental and Reconstructive Medicine, Orthodontics, Nagasaki University, Nagasaki, Japan.
Department of Oral Restitution, Section of Oral Pathology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | - Cecile Itzstein
- Departments of Cell Biology and Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Hard Tissue Engineering, Section of Pharmacology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Suntory Institute for Bioorganic Research, Osaka, Japan.
Department of Pharmacology, Tsurumi University, School of Dental Medicine, Yokohama, Japan.
ProStrakan Pharmaceuticals, Paris, France.
Section of Periodontology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Developmental and Reconstructive Medicine, Orthodontics, Nagasaki University, Nagasaki, Japan.
Department of Oral Restitution, Section of Oral Pathology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | - Masaji Ishiguro
- Departments of Cell Biology and Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Hard Tissue Engineering, Section of Pharmacology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Suntory Institute for Bioorganic Research, Osaka, Japan.
Department of Pharmacology, Tsurumi University, School of Dental Medicine, Yokohama, Japan.
ProStrakan Pharmaceuticals, Paris, France.
Section of Periodontology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Developmental and Reconstructive Medicine, Orthodontics, Nagasaki University, Nagasaki, Japan.
Department of Oral Restitution, Section of Oral Pathology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | - Tatsuya Shibata
- Departments of Cell Biology and Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Hard Tissue Engineering, Section of Pharmacology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Suntory Institute for Bioorganic Research, Osaka, Japan.
Department of Pharmacology, Tsurumi University, School of Dental Medicine, Yokohama, Japan.
ProStrakan Pharmaceuticals, Paris, France.
Section of Periodontology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Developmental and Reconstructive Medicine, Orthodontics, Nagasaki University, Nagasaki, Japan.
Department of Oral Restitution, Section of Oral Pathology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | - Roland Blanque
- Departments of Cell Biology and Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Hard Tissue Engineering, Section of Pharmacology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Suntory Institute for Bioorganic Research, Osaka, Japan.
Department of Pharmacology, Tsurumi University, School of Dental Medicine, Yokohama, Japan.
ProStrakan Pharmaceuticals, Paris, France.
Section of Periodontology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Developmental and Reconstructive Medicine, Orthodontics, Nagasaki University, Nagasaki, Japan.
Department of Oral Restitution, Section of Oral Pathology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | - Anower Hussain Mian
- Departments of Cell Biology and Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Hard Tissue Engineering, Section of Pharmacology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Suntory Institute for Bioorganic Research, Osaka, Japan.
Department of Pharmacology, Tsurumi University, School of Dental Medicine, Yokohama, Japan.
ProStrakan Pharmaceuticals, Paris, France.
Section of Periodontology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Developmental and Reconstructive Medicine, Orthodontics, Nagasaki University, Nagasaki, Japan.
Department of Oral Restitution, Section of Oral Pathology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | - Mariko Takahashi
- Departments of Cell Biology and Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Hard Tissue Engineering, Section of Pharmacology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Suntory Institute for Bioorganic Research, Osaka, Japan.
Department of Pharmacology, Tsurumi University, School of Dental Medicine, Yokohama, Japan.
ProStrakan Pharmaceuticals, Paris, France.
Section of Periodontology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Developmental and Reconstructive Medicine, Orthodontics, Nagasaki University, Nagasaki, Japan.
Department of Oral Restitution, Section of Oral Pathology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | - Yoshifumi Suzuki
- Departments of Cell Biology and Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Hard Tissue Engineering, Section of Pharmacology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Suntory Institute for Bioorganic Research, Osaka, Japan.
Department of Pharmacology, Tsurumi University, School of Dental Medicine, Yokohama, Japan.
ProStrakan Pharmaceuticals, Paris, France.
Section of Periodontology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Developmental and Reconstructive Medicine, Orthodontics, Nagasaki University, Nagasaki, Japan.
Department of Oral Restitution, Section of Oral Pathology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | - Masako Yoshimatsu
- Departments of Cell Biology and Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Hard Tissue Engineering, Section of Pharmacology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Suntory Institute for Bioorganic Research, Osaka, Japan.
Department of Pharmacology, Tsurumi University, School of Dental Medicine, Yokohama, Japan.
ProStrakan Pharmaceuticals, Paris, France.
Section of Periodontology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Developmental and Reconstructive Medicine, Orthodontics, Nagasaki University, Nagasaki, Japan.
Department of Oral Restitution, Section of Oral Pathology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | - Akira Yamaguchi
- Departments of Cell Biology and Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Hard Tissue Engineering, Section of Pharmacology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Suntory Institute for Bioorganic Research, Osaka, Japan.
Department of Pharmacology, Tsurumi University, School of Dental Medicine, Yokohama, Japan.
ProStrakan Pharmaceuticals, Paris, France.
Section of Periodontology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Developmental and Reconstructive Medicine, Orthodontics, Nagasaki University, Nagasaki, Japan.
Department of Oral Restitution, Section of Oral Pathology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | - Pierre Deprez
- Departments of Cell Biology and Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Hard Tissue Engineering, Section of Pharmacology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Suntory Institute for Bioorganic Research, Osaka, Japan.
Department of Pharmacology, Tsurumi University, School of Dental Medicine, Yokohama, Japan.
ProStrakan Pharmaceuticals, Paris, France.
Section of Periodontology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Developmental and Reconstructive Medicine, Orthodontics, Nagasaki University, Nagasaki, Japan.
Department of Oral Restitution, Section of Oral Pathology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | - Patrick Mollat
- Departments of Cell Biology and Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Hard Tissue Engineering, Section of Pharmacology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Suntory Institute for Bioorganic Research, Osaka, Japan.
Department of Pharmacology, Tsurumi University, School of Dental Medicine, Yokohama, Japan.
ProStrakan Pharmaceuticals, Paris, France.
Section of Periodontology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Developmental and Reconstructive Medicine, Orthodontics, Nagasaki University, Nagasaki, Japan.
Department of Oral Restitution, Section of Oral Pathology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | - Ramachandran Murali
- Departments of Cell Biology and Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Hard Tissue Engineering, Section of Pharmacology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Suntory Institute for Bioorganic Research, Osaka, Japan.
Department of Pharmacology, Tsurumi University, School of Dental Medicine, Yokohama, Japan.
ProStrakan Pharmaceuticals, Paris, France.
Section of Periodontology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Developmental and Reconstructive Medicine, Orthodontics, Nagasaki University, Nagasaki, Japan.
Department of Oral Restitution, Section of Oral Pathology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | - Keiichi Ohya
- Departments of Cell Biology and Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Hard Tissue Engineering, Section of Pharmacology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Suntory Institute for Bioorganic Research, Osaka, Japan.
Department of Pharmacology, Tsurumi University, School of Dental Medicine, Yokohama, Japan.
ProStrakan Pharmaceuticals, Paris, France.
Section of Periodontology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Developmental and Reconstructive Medicine, Orthodontics, Nagasaki University, Nagasaki, Japan.
Department of Oral Restitution, Section of Oral Pathology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | - William C. Horne
- Departments of Cell Biology and Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Hard Tissue Engineering, Section of Pharmacology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Suntory Institute for Bioorganic Research, Osaka, Japan.
Department of Pharmacology, Tsurumi University, School of Dental Medicine, Yokohama, Japan.
ProStrakan Pharmaceuticals, Paris, France.
Section of Periodontology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Developmental and Reconstructive Medicine, Orthodontics, Nagasaki University, Nagasaki, Japan.
Department of Oral Restitution, Section of Oral Pathology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| | - Roland Baron
- Departments of Cell Biology and Orthopaedics, Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Hard Tissue Engineering, Section of Pharmacology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Suntory Institute for Bioorganic Research, Osaka, Japan.
Department of Pharmacology, Tsurumi University, School of Dental Medicine, Yokohama, Japan.
ProStrakan Pharmaceuticals, Paris, France.
Section of Periodontology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Developmental and Reconstructive Medicine, Orthodontics, Nagasaki University, Nagasaki, Japan.
Department of Oral Restitution, Section of Oral Pathology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan.
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
| |
Collapse
|
30
|
Wu PL, Lee SC, Chuang CC, Mori S, Akakura N, Wu WG, Takada Y. Non-cytotoxic cobra cardiotoxin A5 binds to alpha(v)beta3 integrin and inhibits bone resorption. Identification of cardiotoxins as non-RGD integrin-binding proteins of the Ly-6 family. J Biol Chem 2006; 281:7937-45. [PMID: 16407244 DOI: 10.1074/jbc.m513035200] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Severe tissue necrosis with a retarded wound healing process is a major symptom of a cobra snakebite. Cardiotoxins (CTXs) are major components of cobra venoms that belong to the Ly-6 protein family and are implicated in tissue damage. The interaction of the major CTX from Taiwan cobra, i.e. CTX A3, with sulfatides in the cell membrane has recently been shown to induce pore formation and cell internalization and to be responsible for cytotoxicity in cardiomyocytes (Wang, C.-H., Liu, J.-H., Lee, S.-C., Hsiao, C.-D., and Wu, W.-g. (2006) J. Biol. Chem. 281, 656-667). We show here that one of the non-cytotoxic CTXs, i.e. CTX A5 or cardiotoxin-like basic polypeptide, from Taiwan cobra specifically bound to alpha(v)beta3 integrin and inhibited bone resorption activity. We found that both membrane-bound and recombinant soluble alpha(v)beta3 integrins bound specifically to CTX A5 in a dose-dependent manner. Surface plasmon resonance analysis showed that human soluble alpha(v)beta3 bound to CTX A5 with an apparent affinity of approximately 0.3 microM. Calf pulmonary artery endothelial cells, which constitutively express alpha(v)beta3, showed a CTX A5 binding profile similar to that of membrane-bound and soluble alpha(v)beta3 integrins, suggesting that endothelial cells are a potential target for CTX action. We tested whether CTX A5 inhibits osteoclast differentiation and bone resorption, a process known to be involved in alpha(v)beta3 binding and inhibited by RGD-containing peptides. We demonstrate that CTX A5 inhibited both activities at a micromolar range by binding to murine alpha(v)beta3 integrin in osteoclasts and that CTX A5 co-localized with beta3 integrin. Finally, after comparing the integrin binding affinity among CTX homologs, we propose that the amino acid residues near the two loops of CTX A5 are involved in integrin binding. These results identify CTX A5 as a non-RGD integrin-binding protein with therapeutic potential as an integrin antagonist.
Collapse
Affiliation(s)
- Po-Long Wu
- Institute of Bioinformatics and Structural Biology, National Tsing Hua University, Hsinchu 30043, Taiwan
| | | | | | | | | | | | | |
Collapse
|
31
|
|
32
|
Murphy MG, Cerchio K, Stoch SA, Gottesdiener K, Wu M, Recker R. Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2005; 90:2022-8. [PMID: 15687321 DOI: 10.1210/jc.2004-2126] [Citation(s) in RCA: 107] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The alphaVbeta3 integrin (vitronectin receptor) plays a pivotal role in bone resorption. We hypothesized that L-000845704, an alphaVbeta3 integrin antagonist, would potently inhibit bone resorption, thereby increasing bone mass as assessed by bone mineral density (BMD) in women with postmenopausal osteoporosis. In a multicenter, randomized, double-blind, placebo-controlled, 12-month study, 227 women (average 63 yr) with low lumbar spine or femoral neck BMD were randomly assigned to receive 100 or 400 mg L-000845704 once daily (qd), 200 mg L-000845704 twice daily (bid), or placebo. L-000845704 increased lumbar spine BMD (2.1, 3.1, and 3.5% for the 100-mg-qd, 400-mg-qd, and 200-mg-bid treatment groups, respectively, vs. -0.1% for placebo; P < 0.01 all treatments vs. placebo). Only 200 mg L-000845704 bid significantly increased BMD at the hip (1.7 vs. 0.3% for placebo; P < 0.03) and femoral neck (2.4 vs. 0.7% for placebo; P < 0.05). No L-000845704 group increased total body BMD. All doses of L-000845704 resulted in a similar approximately 42% decrease from baseline of N-telopeptide cross-links (P < 0.001 vs. placebo). L-000845704 was generally well tolerated; adverse events resulting in discontinuation from the study were relatively infrequent. In conclusion, the antiresorptive effect of the alphaVbeta3 integrin antagonist L-000845704 translated into significant increases in lumbar spine BMD. Furthermore, 200 mg L-000845704 bid provided efficacy at the hip sites. These data suggest that the alphaVbeta3 integrin antagonist L-000845704 could be developed as an effective therapeutic agent for osteoporosis.
Collapse
Affiliation(s)
- M G Murphy
- Merck Research Laboratories, Building 5W, Sentry Rahway, NJ 07065, USA.
| | | | | | | | | | | |
Collapse
|
33
|
|
34
|
Coleman PJ, Brashear KM, Askew BC, Hutchinson JH, McVean CA, Duong LT, Feuston BP, Fernandez-Metzler C, Gentile MA, Hartman GD, Kimmel DB, Leu CT, Lipfert L, Merkle K, Pennypacker B, Prueksaritanont T, Rodan GA, Wesolowski GA, Rodan SB, Duggan ME. Nonpeptide alphavbeta3 antagonists. Part 11: discovery and preclinical evaluation of potent alphavbeta3 antagonists for the prevention and treatment of osteoporosis. J Med Chem 2004; 47:4829-37. [PMID: 15369386 DOI: 10.1021/jm049874c] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
3-(S)-Pyrimidin-5-yl-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid (5e) and 3-(S)-(methylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid (5f) were identified as potent and selective antagonists of the alpha(v)beta(3) receptor. These compounds have excellent in vitro profiles (IC(50) = 0.07 and 0.08 nM, respectively), significant unbound fractions in human plasma (6 and 4%), and good pharmacokinetics in rat, dog, and rhesus monkey. On the basis of the efficacy shown in an in vivo model of bone turnover following once-daily oral administration, these two compounds were selected for clinical development for the treatment of osteoporosis.
Collapse
Affiliation(s)
- Paul J Coleman
- Department of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A, Destefano J, Rodan GA, Duong LT. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. ACTA ACUST UNITED AC 2004; 50:1193-206. [PMID: 15077302 DOI: 10.1002/art.20124] [Citation(s) in RCA: 422] [Impact Index Per Article: 21.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
OBJECTIVE It has been suggested that subchondral bone remodeling plays a role in the progression of osteoarthritis (OA). To test this hypothesis, we characterized the changes in the rat anterior cruciate ligament transection (ACLT) model of OA and evaluated the effects of alendronate (ALN), a potent inhibitor of bone resorption, on cartilage degradation and on osteophyte formation. METHODS Male Sprague-Dawley rats underwent ACLT or sham operation of the right knee. Animals were then treated with ALN (0.03 and 0.24 microg/kg/week subcutaneously) and necropsied at 2 or 10 weeks postsurgery. OA changes were evaluated. Subchondral bone volume and osteophyte area were measured by histomorphometric analysis. Coimmunostaining for transforming growth factor beta (TGF beta), matrix metalloproteinase 9 (MMP-9), and MMP-13 was performed to investigate the effect of ALN on local activation of TGF beta. RESULTS ALN was chondroprotective at both dosages, as determined by histologic criteria and collagen degradation markers. ALN suppressed subchondral bone resorption, which was markedly increased 2 weeks postsurgery, and prevented the subsequent increase in bone formation 10 weeks postsurgery, in the untreated tibial plateau of ACLT joints. Furthermore, ALN reduced the incidence and area of osteophytes in a dose-dependent manner. ALN also inhibited vascular invasion into the calcified cartilage in rats with OA and blocked osteoclast recruitment to subchondral bone and osteophytes. ALN treatment reduced the local release of active TGF beta, possibly via inhibition of MMP-13 expression in articular cartilage and MMP-9 expression in subchondral bone. CONCLUSION Subchondral bone remodeling plays an important role in the pathogenesis of OA. ALN or other inhibitors of bone resorption could potentially be used as disease-modifying agents in the treatment of OA.
Collapse
Affiliation(s)
- Tadashi Hayami
- Merck Research Laboratories, West Point, Pennsylvania 19486, USA
| | | | | | | | | | | | | | | |
Collapse
|
36
|
Yasuda N, Hsiao Y, Jensen MS, Rivera NR, Yang C, Wells KM, Yau J, Palucki M, Tan L, Dormer PG, Volante RP, Hughes DL, Reider PJ. An Efficient Synthesis of an αvβ3 Antagonist. J Org Chem 2004; 69:1959-66. [PMID: 15058940 DOI: 10.1021/jo030297u] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A practical preparation of an alpha(v)beta(3) antagonist is reported. The antagonist consists of three key components, a tetrahydronaphthyridine moiety, a beta-alanine moiety, and a central imidazolidone moiety. The tetrahydronaphthyridine component was prepared using two different methods, both of which relied on variations of the Friedländer reaction to establish the desired regiochemistry. The beta-alanine component was prepared using Davies' asymmetric 1,4-addition methodology as the key stereo-defining step. The central imidazolidone portion was created from these two components using an effective three-step cyclization protocol. Thus, a highly convergent process for the drug candidate was defined.
Collapse
Affiliation(s)
- Nobuyoshi Yasuda
- Department of Process Research, Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Wang J, Breslin MJ, Coleman PJ, Duggan ME, Hunt CA, Hutchinson JH, Leu CT, Rodan SB, Rodan GA, Duong LT, Hartman GD. Non-peptide α v β 3 antagonists. Part 7: 3-Substituted tetrahydro- [1,8] naphthyridine derivatives. Bioorg Med Chem Lett 2004; 14:1049-52. [PMID: 15013021 DOI: 10.1016/j.bmcl.2003.11.036] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2003] [Accepted: 11/13/2003] [Indexed: 11/26/2022]
Abstract
A series of 3-substituted tetrahydro-[1,8]naphthyridine containing alpha(v)beta(3) antagonists was prepared. A comparison of their in vitro IC(50) values to the electron properties of the 3-substituents revealed a good linear Hammett correlation (rho=-1.96, R(2)=0.959). Electron-withdrawing groups at the 3-position of the tetrahydro-[1,8]naphthyridine decreased potency while electron-donating groups enhanced potency.
Collapse
Affiliation(s)
- Jiabing Wang
- Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 4, West Point, PA 19486, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Perkins JJ, Duong LT, Fernandez-Metzler C, Hartman GD, Kimmel DB, Leu CT, Lynch JJ, Prueksaritanont T, Rodan GA, Rodan SB, Duggan ME, Meissner RS. Non-peptide α v β 3 antagonists: Identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint. Bioorg Med Chem Lett 2003; 13:4285-8. [PMID: 14643310 DOI: 10.1016/j.bmcl.2003.09.055] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Antagonists of the integrin receptor alpha(v)beta(3) are expected to have utility in the treatment of osteoporosis through inhibition of bone resorption. A series of potent, chain-shortened, pyrrolidinone-containing alpha(v)beta(3) receptor antagonists is described. Two sets of diasteromeric pairs of high-affinity antagonists demonstrated marked differences in log P values, which translated into differing dog pharmacokinetic properties. One member of this set was demonstrated to be effective in reducing bone resorption in rats.
Collapse
Affiliation(s)
- James J Perkins
- Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Hutchinson JH, Halczenko W, Brashear KM, Breslin MJ, Coleman PJ, Duong LT, Fernandez-Metzler C, Gentile MA, Fisher JE, Hartman GD, Huff JR, Kimmel DB, Leu CT, Meissner RS, Merkle K, Nagy R, Pennypacker B, Perkins JJ, Prueksaritanont T, Rodan GA, Varga SL, Wesolowski GA, Zartman AE, Rodan SB, Duggan ME. Nonpeptide αvβ3 Antagonists. 8. In Vitro and in Vivo Evaluation of a Potent αvβ3 Antagonist for the Prevention and Treatment of Osteoporosis. J Med Chem 2003; 46:4790-8. [PMID: 14561098 DOI: 10.1021/jm030306r] [Citation(s) in RCA: 75] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
3(S)-(6-methoxypyridin-3-yl)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-[1,8]-naphthyridin-2-yl)propyl]imidazolidin-1-yl]propionic acid 6 was identified as a potent and selective antagonist of the alpha(v)beta(3) receptor. This compound has an excellent in vitro profile (IC(50) = 0.08 nM), a significant unbound fraction in human plasma (12%), and good pharmacokinetics in rat, dog, and rhesus monkey. On the basis of the efficacy shown in three in vivo models of bone turnover, the compound was selected for clinical development. To support the ongoing metabolism and safety studies, a novel strategy was employed in which a series of oxidized derivatives of 6 were prepared by exposure of 6 (or the methyl ester) to chemical oxidizing agents. These products proved useful in the identification of active metabolites generated by either in vitro or in vivo metabolism.
Collapse
Affiliation(s)
- John H Hutchinson
- Department of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Dolce C, Vakani A, Archer L, Morris-Wiman JA, Holliday LS. Effects of echistatin and an RGD peptide on orthodontic tooth movement. J Dent Res 2003; 82:682-6. [PMID: 12939350 DOI: 10.1177/154405910308200905] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
We tested whether orthodontic tooth movement (OTM) could be blocked by local administration of echistatin or an arginine-glycine-aspartic acid (RGD) peptide, agents known to perturb bone remodeling, adjacent to maxillary molars in rats. These molecules were incorporated into ethylene-vinyl acetate (ELVAX), a non-biodegradable, sustained-release polymer. In vitro experiments showed that the echistatin and RGD peptide were released from ELVAX in active forms at levels sufficient to disrupt osteoclasts. Biotinylated RGD peptide was released from ELVAX into the PDL after surgical implantation. ELVAX loaded with either RGD peptide or echistatin and surgically implanted next to the maxillary molars inhibited orthodontic tooth movement (p < 0.01). The RGD peptide also reduced molar drift (p < 0.05). This study shows the feasibility of using ELVAX to deliver integrin inhibitors adjacent to teeth to limit local tooth movement in response to orthodontic forces.
Collapse
Affiliation(s)
- C Dolce
- Department of Orthodontics, College of Dentistry, University of Florida, Box 100444, JHMHC, Gainesville, FL 32610-0444, USA.
| | | | | | | | | |
Collapse
|
41
|
Rader C, Sinha SC, Popkov M, Lerner RA, Barbas CF. Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst. Proc Natl Acad Sci U S A 2003; 100:5396-400. [PMID: 12702756 PMCID: PMC154356 DOI: 10.1073/pnas.0931308100] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Proposing that a blend of the chemical diversity of small synthetic molecules with the immunological characteristics of the antibody molecule will lead to therapeutic agents with superior properties, we here present a device that equips small synthetic molecules with both effector function and long serum half-life of a generic antibody molecule. As a prototype, we developed a targeting device that is based on the formation of a covalent bond of defined stoichiometry between a 1,3-diketone derivative of an integrin alpha(v)beta(3) and alpha(v)beta(5) targeting Arg-Gly-Asp peptidomimetic and the reactive lysine of aldolase antibody 38C2. The resulting complex was shown to (i) spontaneously assemble in vitro and in vivo, (ii) selectively retarget antibody 38C2 to the surface of cells expressing integrins alpha(v)beta(3) and alpha(v)beta(5), (iii) dramatically increase the circulatory half-life of the Arg-Gly-Asp peptidomimetic, and (iv) effectively reduce tumor growth in animal models of human Kaposi's sarcoma and colon cancer. This immunotherapeutic has the potential to target a variety of human cancers, acting on both the vasculature that supports tumor growth as well as the tumor cells themselves. Further, by use of a generic antibody molecule that forms a covalent bond with a 1,3-diketone functionality, essentially any compound can be turned into an immunotherapeutic agent thereby not only increasing the diversity space that can be accessed but also multiplying the therapeutic effect.
Collapse
Affiliation(s)
- Christoph Rader
- Department of Molecular Biology and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
| | | | | | | | | |
Collapse
|
42
|
Lakkakorpi PT, Bett AJ, Lipfert L, Rodan GA, Duong LT. PYK2 autophosphorylation, but not kinase activity, is necessary for adhesion-induced association with c-Src, osteoclast spreading, and bone resorption. J Biol Chem 2003; 278:11502-12. [PMID: 12514172 DOI: 10.1074/jbc.m206579200] [Citation(s) in RCA: 98] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Proline-rich tyrosine kinase 2 (PYK2) is the main adhesion-induced kinase in bone-resorbing osteoclasts. Previous studies have shown that ligation of alpha(v)beta(3) integrin in osteoclasts induces c-Src-dependent tyrosine phosphorylation and PYK2 activation, leading to cytoskeletal rearrangement, migration, and polarization of these cells. In this study, we examined the role of PYK2 kinase activity and its major autophosphorylation site in adhesion-dependent signaling and cytoskeletal organization during osteoclast spreading and migration. By infecting pre-fusion osteoclasts using recombinant adenovirus expressing PYK2 and its mutants, we demonstrated that mutation at the autophosphorylation site (Y402F) abolishes PYK2 association with c-Src and reduces significantly phosphorylation at tyrosines 579/580 and 881 resulting in inhibition of osteoclast spreading and bone resorption. Overexpression of the kinase-dead PYK2(K475A) mutant had no effect on cell spreading, interaction with c-Src, or the phosphorylation level of Tyr-402, Tyr-579/580, and Tyr-881 relative to PYK2(wt)-expressing cells. Taken together these findings suggest that Tyr-402 is the major docking site for c-Src and can be phosphorylated by another tyrosine kinase in osteoclasts but not in HEK293 cells. Interestingly, both PYK2(Y402F) and PYK2(K457A) translocate normally to podosomes and have no effect on macrophage colony-stimulating factor-induced osteoclast migration. Whereas PYK2(Y402F) dominant negatively blocks osteoclast spreading and bone resorption, PYK2(K457A) may function in part as an adaptor by initially recruiting c-Src to the adhesion complex, which appears to activate PYK2 by phosphorylating additional tyrosines in its regulatory and C-terminal domains. We thus concluded that phosphorylation at Tyr-402 in PYK2 is essential in the regulation of adhesion-dependent cytoskeletal organization in osteoclasts.
Collapse
Affiliation(s)
- Parvi T Lakkakorpi
- Department of Bone Biology and Osteoporosis Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
| | | | | | | | | |
Collapse
|
43
|
Lark MW, Stroup GB, Dodds RA, Kapadia R, Hoffman SJ, Hwang SM, James IE, Lechowska B, Liang X, Rieman DJ, Salyers KL, Ward K, Smith BR, Miller WH, Huffman WF, Gowen M. Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat. J Bone Miner Res 2001; 16:319-27. [PMID: 11204432 DOI: 10.1359/jbmr.2001.16.2.319] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
An orally active, nonpeptide Arg-Gly-Asp (RGD) mimetic alpha(v)beta3 antagonist, (S)-3-Oxo-8-[2-[6-(methylamino)-pyridin-2-yl]-1-ethoxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid (compound 1), has been generated, which prevented net bone loss and inhibited cancellous bone turnover in vivo. The compound binds alpha(v)beta3 and the closely related integrin alpha(v)beta5 with low nanomolar affinity but binds only weakly to the related integrins alpha(IIb)beta3, and alpha5beta1. Compound 1 inhibited alpha(v)beta3-mediated cell adhesion with an IC50 = 3 nM. More importantly, the compound inhibited human osteoclast-mediated bone resorption in vitro with an IC50 = 11 nM. In vivo, compound 1 inhibited bone resorption in a dose-dependent fashion, in the acute thyroparathyroidectomized (TPTX) rat model of bone resorption with a circulating EC50 approximately 20 microM. When dosed orally at 30 mg/kg twice a day (b.i.d.) in the chronic ovariectomy (OVX)-induced rat model of osteopenia, compound 1 also prevented bone loss. At doses ranging from 3 to 30 mg/kg b.i.d., compound 1 partially prevented the OVX-induced increase in urinary deoxypyridinoline. In addition, the compound prevented the OVX-induced reduction in cancellous bone volume (BV), trabecular number (Tb.N), and trabecular thickness (Tb.Th), as assessed by quantitative microcomputerized tomography (microCT) and static histomorphometry. Furthermore, both the 10-mg/kg and 30-mg/kg doses of compound prevented the OVX-induced increase in bone turnover, as measured by percent osteoid perimeter (%O.Pm). Together, these data indicate that the alpha(v)beta3 antagonist compound 1 inhibits OVX-induced bone loss. Mechanistically, compound 1 prevents bone loss in vivo by inhibiting osteoclast-mediated bone resorption, ultimately preventing cancellous bone turnover.
Collapse
Affiliation(s)
- M W Lark
- Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Hamill TG, Duggan ME, Perkins JJ. The synthesis of the ?v?3 integrin receptor ligand [125I]L-775,219. J Labelled Comp Radiopharm 2001. [DOI: 10.1002/jlcr.432] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
45
|
Badger AM, Blake S, Kapadia R, Sarkar S, Levin J, Swift BA, Hoffman SJ, Stroup GB, Miller WH, Gowen M, Lark MW. Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. ARTHRITIS AND RHEUMATISM 2001; 44:128-37. [PMID: 11212150 DOI: 10.1002/1529-0131(200101)44:1<128::aid-anr17>3.0.co;2-m] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
OBJECTIVE To evaluate the effects of SB 273005, a potent, orally active nonpeptide antagonist of the integrin avbeta3 vitronectin receptor, on joint integrity in rats with adjuvant-induced arthritis (AIA). METHODS Male Lewis rats with AIA were orally dosed either prophylactically (days 0-20) or therapeutically (days 10-20) with SB 273005. Efficacy was determined by measurement of paw inflammation, assessment of bone mineral density using dual-energy x-ray absorptiometry (DEXA), magnetic resonance imaging (MRI), and histologic evaluation. RESULTS SB 273005 is a potent antagonist of the closely related integrins, avbeta3 (Ki = 1.2 nM) and alphavbeta5 (Ki = 0.3 nM). When SB 273005 was administered prophylactically to AIA rats twice per day, it inhibited paw edema at doses of 10, 30, and 60 mg/kg, by 40%, 50%, and 52%, respectively. Therapeutic administration twice daily was also effective, and a reduction in paw edema was observed at 30 mg/kg and 60 mg/kg of the antagonist (by 36% and 48%, respectively). SB 273005 was also effective when administered once per day, both prophylactically and therapeutically. Significant improvement in joint integrity in treated rats was shown using DEXA and MRI analyses. These findings were confirmed histologically, and significant protection of bone, cartilage, and soft tissue was observed within the joint. CONCLUSION Symptoms of AIA in rats were significantly reduced by either prophylactic or therapeutic treatment with the alphavbeta3 antagonist, SB 273005. Measurements of paw inflammation and of bone, cartilage, and soft tissue structure indicated that this compound exerts a protective effect on joint integrity and thus appears to have disease-modifying properties.
Collapse
Affiliation(s)
- A M Badger
- SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Affiliation(s)
- L T Duong
- Department of Bone Biology and Osteoporosis, Merck Research Laboratories, West Point, PA 19486, USA.
| | | |
Collapse
|
47
|
Abstract
The strength and integrity of our bones depends on maintaining a delicate balance between bone resorption by osteoclasts and bone formation by osteoblasts. As we age or as a result of disease, this delicate balancing act becomes tipped in favor of osteoclasts so that bone resorption exceeds bone formation, rendering bones brittle and prone to fracture. A better understanding of the biology of osteoclasts and osteoblasts is providing opportunities for developing therapeutics to treat diseases of bone. Drugs that inhibit the formation or activity of osteoclasts are valuable for treating osteoporosis, Paget's disease, and inflammation of bone associated with rheumatoid arthritis or periodontal disease. Far less attention has been paid to promoting bone formation with, for example, growth factors or hormones, an approach that would be a valuable adjunct therapy for patients receiving inhibitors of bone resorption.
Collapse
Affiliation(s)
- G A Rodan
- Merck Research Laboratories, West Point, PA 19486, USA. St. Vincent's Institute of Medical Research, Melbourne 3065, Australia.
| | | |
Collapse
|
48
|
Chen YC, Bab I, Mansur N, Muhlrad A, Shteyer A, Namdar-Attar M, Gavish H, Vidson M, Chorev M. Structure-bioactivity of C-terminal pentapeptide of osteogenic growth peptide [OGP(10-14)]. THE JOURNAL OF PEPTIDE RESEARCH : OFFICIAL JOURNAL OF THE AMERICAN PEPTIDE SOCIETY 2000; 56:147-56. [PMID: 11007271 DOI: 10.1034/j.1399-3011.2000.00763.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The amino acid sequence of osteogenic growth peptide (OGP) consists of 14 residues identical to the C-terminal tail of histone H4. Native and synthetic OGP are mitogenic to osteoblastic and fibroblastic cells and enhance osteogenesis and hematopoiesis in vivo. The C-terminal truncated pentapeptide of OGP, H-Tyr-Gly-Phe-Gly-Gly-OH [OGP(10-14)], is a naturally occurring osteoblastic mitogen, equipotent to OGP. The present study assesses the role of individual amino acid residues and side chains in the OGP(10-14) mitogenic activity which showed a very high correlation between osteoblastic and fibroblastic cell cultures. Truncation of either Tyr10 or its replacement by Ala or D-Ala resulted in substantial, but not complete, loss of activity. Nevertheless, only a small loss of activity was observed following removal of the Tyr10 amino group. No further loss occurred consequent to the monoiodination of desaminoTyr10 on meta-position. However, a marked decrease in proliferative activity followed removal of the Tyr10 phenolic or the Phe12 aromatic group. Loss of activity of a similar magnitude also occurred subsequent to replacing Gly11 with L- or D-Ala. Approximately 50% loss of mitogenic activity occurred subsequent to truncation of Gly14 or blocking the C-terminal group as the methyl ester. All other modifications of the C-terminus and L- or D-Ala substitution of Gly13 resulted in 70-97% decrease in activity. Collectively, these data suggest that the integrity of the pharmacophores presented by Tyr and Phe side chains, as well as the Gly residues at the C-terminus, are important for optimal bioactivity of OGP(10-14).
Collapse
Affiliation(s)
- Y C Chen
- Bone Laboratory, Institute of Dental Sciences, Faculty of Dental Medicine, The Hebrew University of Jerusalem, Israel.
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Daci E, Verstuyf A, Moermans K, Bouillon R, Carmeliet G. Mice lacking the plasminogen activator inhibitor 1 are protected from trabecular bone loss induced by estrogen deficiency. J Bone Miner Res 2000; 15:1510-6. [PMID: 10934649 DOI: 10.1359/jbmr.2000.15.8.1510] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Bone turnover requires the interaction of several proteases during the resorption phase. Indirect evidence suggests that the plasminogen activator/plasmin pathway is involved in bone resorption and turnover, and recently we have shown that this cascade plays a role in the degradation of nonmineralized bone matrix in vitro. To elucidate the role of the plasminogen activator inhibitor 1 (PAI-1) in bone turnover in vivo, bone metabolism was analyzed in mice deficient in the expression of PAI-1 gene (PAI-1-/-) at baseline (8-week-old mice) and 4 weeks after ovariectomy (OVX) or sham operation (Sham) and compared with wild-type (WT) mice. PAI-1 inactivation was without any effect on bone metabolism at baseline or in Sham mice. However, significant differences were observed in the response of WT and PAI-1-/- mice to ovariectomy. The OVX WT mice showed, as expected, decreased trabecular bone volume (BV/TV) and increased osteoid surface (OS/BS) and bone formation rate (BFR), as assessed by histomorphometric analysis of the proximal tibial metaphysis. In contrast, no significant change in any of the histomorphometric variables studied was detected in PAI-1-/- mice after ovariectomy. As a result, the OVX PAI-1-/- had a significantly higher BV/TV, lower OS/BS, lower mineral apposition rate (MAR) and BFR when compared with the OVX WT mice. However, a comparable decrease in the cortical thickness was observed in OVX PAI-1-/- and WT mice. In addition, the cortical mineral content and density assessed in the distal femoral metaphysis by peripheral quantitative computed tomography (pQCT), decreased significantly after ovariectomy, without difference between PAI-1-/- mice and WT mice. In conclusion, basal bone turnover and bone mass are only minimally affected by PAI-1 inactivation. In conditions of estrogen deficiency, PAI-1 inactivation protects against trabecular bone loss but does not affect cortical bone loss, suggesting a site-specific role for PAI-1 in bone turnover.
Collapse
Affiliation(s)
- E Daci
- Laboratorium voor Experimentele Geneeskunde en Endocrinologie, Katholieke Universiteit Leuven, Belgium
| | | | | | | | | |
Collapse
|
50
|
Visentin L, Dodds RA, Valente M, Misiano P, Bradbeer JN, Oneta S, Liang X, Gowen M, Farina C. A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats. J Clin Invest 2000; 106:309-18. [PMID: 10903347 PMCID: PMC380241 DOI: 10.1172/jci6145] [Citation(s) in RCA: 96] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/1998] [Accepted: 06/14/2000] [Indexed: 12/11/2022] Open
Abstract
A potent and selective inhibitor of the osteoclastic V-H(+)-ATPase, (2Z,4E)-5-(5,6-dichloro-2-indolyl)-2-methoxy-N-(1,2,2,6, 6-pentamethylpiperidin-4-yl)-2,4-pentadienamide (SB 242784), was evaluated in two animal models of bone resorption. SB 242784 completely prevented retinoid-induced hypercalcemia in thyroparathyroidectomized (TPTX) rats when administered orally at 10 mg/kg. SB 242784 was highly efficacious in the prevention of ovariectomy-induced bone loss in the rat when administered orally for 6 months at 10 mg/kg/d and was partially effective at 5 mg/kg/d. Its activity was demonstrated by measurement of bone mineral density (BMD), biochemical markers of bone resorption, and histomorphometry. SB 242784 was at least as effective in preventing bone loss as an optimal dose of estrogen. There were no adverse effects of compound administration and no effects on kidney function or urinary acidity. Selectivity of the inhibitor was further studied using an in situ cytochemical assay for bafilomycin-sensitive V-H(+)-ATPase using sections of osteoclastoma and numerous other tissues. SB 242784 inhibited the osteoclast enzyme at 1,000-fold lower concentrations than enzymes in any of the other tissues evaluated. SB 242784 demonstrates the utility of selective inhibition of the osteoclast V-H(+)-ATPase as a novel approach to the prevention of bone loss in humans.
Collapse
Affiliation(s)
- L Visentin
- SmithKline Beecham S.p.A, Milano, Italy. SmithKline Beecham Pharmaceuticals, Bone and Cartilage Biology, King of Prussia, Pennsylvania, USA
| | | | | | | | | | | | | | | | | |
Collapse
|